title: Five-year survival in patients with ST-segment-elevation myocardial infarction according to modalities of reperfusion therapy: the French Registry on Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) 2005 Cohort.
abstract: BACKGROUND
  Although primary percutaneous coronary intervention (pPCI) is the preferred reperfusion method for ST-segment-elevation myocardial infarction, it remains difficult to implement in many areas, and fibrinolytic therapy is still widely used.
  
  
  RESULTS
  We assessed 5-year mortality in patients with ST-segment-elevation myocardial infarction from the French Registry of Acute ST-Elevation or Non-ST Elevation Myocardial Infarction (FAST-MI) 2005 according to use and type of reperfusion therapy. Of 1492 patients with ST-segment-elevation myocardial infarction with a first call ≤12 hours from onset, 447 (30%) received fibrinolysis (66% prehospital; 97% with subsequent angiography, 84% with subsequent PCI), 583 (39%) had pPCI, and 462 (31%) received no reperfusion. Crude 5-year survival was 88% for the fibrinolytic-based strategy, 83% for pPCI, and 59% for no reperfusion. Adjusted hazard ratios for 5-year death were 0.73 (95% confidence interval, 0.50-1.06) for fibrinolysis versus pPCI, 0.57 (95% confidence interval, 0.36-0.88) for prehospital fibrinolysis versus pPCI, and 0.63 (95% confidence interval, 0.34-0.91) for fibrinolysis versus pPCI beyond 90 minutes of call in patients having called ≤180 minutes from onset. In propensity score-matched populations, however, survival rates were not significantly different for fibrinolysis and pPCI, both in the whole population (88% lysis, 85% pPCI) and in the population seen early (87% fibrinolysis, 85% pPCI beyond 90 minutes from call).
  
  
  CONCLUSIONS
  In a real-world setting, on a nationwide scale, a pharmaco-invasive strategy constitutes a valid alternative to pPCI, with 5-year survival at least equivalent to that of the reference reperfusion method.
  
  
  BACKGROUND
  www.clinicaltrials.gov. Unique identifier: NCT00673036.
authors.affiliation: Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France (N.D., E.P.); INSERM U 970, Paris, France (N.D., E.P.); Université Paris Descartes, Paris, France (N.D., E.P.); Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France (P.G.S.); INSERM U 698, Paris, France (P.G.S.); Université Paris Diderot, Paris, France (P.G.S.); Centre Hospitalier Régional Universitaire de Lille, Lille, France (P.G.); Hôpital Jean Minjoz, Besançon, France (F.S.); Université de Franche Comté, Besançon, France (F.S.); Centre Hospitalier d'Annecy, Annecy, France (L.B.); Hôpital du Bocage, Dijon, France (Y.C.); Université de Bourgogne, Dijon, France (Y.C.); Clinique Pasteur, Toulouse, France (J. Fajadet); Centre Hospitalier Régional de Metz-Thionville, Metz, France (K.K.); Hôpital du Haut Levêque, Pessac, France (P.C.); Université Bordeaux Segalen, Bordeaux, France (P.C.); Hôpital Rangueil, Toulouse, France (J. Ferrières); INSERM U1027, Toulouse, France (J. Ferrières); Université Paul Sabatier Toulouse, Toulouse, France (J. Ferrières); Assistance Publique-Hôpitaux de Paris, Hôpital St Antoine, Unité de Recherche Clinique (URCEST), Paris, France (T.S.); INSERM U698, Paris, France (T.S.); and Université Pierre et Marie Curie, Paris, France (T.S.).
authors.forename: Nicolas
authors.initials: N
authors.lastname: Danchin
authors.forename: Etienne
authors.initials: E
authors.lastname: Puymirat
authors.forename: Philippe Gabriel
authors.initials: PG
authors.lastname: Steg
authors.forename: Patrick
authors.initials: P
authors.lastname: Goldstein
authors.forename: François
authors.initials: F
authors.lastname: Schiele
authors.forename: Loïc
authors.initials: L
authors.lastname: Belle
authors.forename: Yves
authors.initials: Y
authors.lastname: Cottin
authors.forename: Jean
authors.initials: J
authors.lastname: Fajadet
authors.forename: Khalife
authors.initials: K
authors.lastname: Khalife
authors.forename: Pierre
authors.initials: P
authors.lastname: Coste
authors.forename: Jean
authors.initials: J
authors.lastname: Ferrières
authors.forename: Tabassome
authors.initials: T
authors.lastname: Simon
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D015425:Myocardial Reperfusion / Q000401:mortality / Q000639:trends; D062645:Percutaneous Coronary Intervention / Q000401:mortality* / Q000639:trends; D012042:Registries; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents
keywords: myocardial infarction; percutaneous coronary intervention; pharmacologic actions; time